Mounjaro Face (Zepbound Face): What Tirzepatide Does to Your Face, by the Numbers

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

Mounjaro face, also called Zepbound face, is facial fat and volume loss from the rapid weight loss tirzepatide can bring, not a proven drug effect. No study has measured faces on tirzepatide, but a 20-person imaging study of mixed GLP-1 users found midface volume fell about 7% per 10 kg lost (Sharma et al., 2025). Evidence: Limited.

Decisions about your GLP-1 dose or treatment belong with your prescriber. This article describes studies. It isn't medical advice.

Mounjaro and Zepbound are the same once-weekly drug, tirzepatide, made by Eli Lilly. In the US, Mounjaro is approved for type 2 diabetes and isn't FDA-approved for weight loss. Zepbound is the US weight-management brand. In the UK, Mounjaro is the weight-loss brand, so "Mounjaro face" fills UK search results while "Zepbound face" is the US term. For treatment options across all GLP-1 drugs, see our guide to how to fix Ozempic face.

This page covers tirzepatide specifically: what changes, how much, and what body-composition scans show. For the semaglutide version, see Wegovy face before and after. For the wider cluster, start with our GLP-1 skin guide.

Key takeaways

• Cleveland Clinic describes "Ozempic face," which includes the tirzepatide version, as a result of rapid weight loss rather than of the drug itself. No trial has measured faces on tirzepatide (Cleveland Clinic, 2025).
• In a 20-person CT/MRI study of mixed GLP-1 users, midface volume dropped about 7% per 10 kg lost, mostly from fat just under the skin (Sharma et al., 2025).
• In a 160-person SURMOUNT-1 body-scan substudy, about 75% of weight lost on tirzepatide was fat and 25% lean mass, the same split as placebo (Look et al., 2025).
• A 2026 meta-analysis of 20 RCTs put tirzepatide's lean share of weight lost at 25.4%, vs 35.2% for semaglutide and 17.5% for lifestyle plus resistance training (Eisa and Barood, 2026).
• In SURMOUNT-5, people lost a mean 20.2% of body weight on tirzepatide vs 13.7% on semaglutide, but faces weren't measured (Aronne et al., 2025).

What is Mounjaro face?

Mounjaro face is a nickname, not a medical term, for the hollower, looser face some people notice after losing weight on tirzepatide. Cleveland Clinic endocrinologist Vinni Makin, MD, explains that "'Ozempic face' isn't a side effect of the medication itself. Rather, it's a side effect of the rapid weight loss the medication can bring" (Cleveland Clinic, 2025). The same page says the term isn't limited to Ozempic and is often linked with both semaglutide and tirzepatide.

The American Academy of Dermatology (AAD) says patients describe less plumpness, sagging, wrinkles and a crepe-like texture. Dermatologists see the change as "partly caused by rapid weight loss" (AAD, 2026). A systematic review of 13 studies plus 1 abstract on surgical and medical weight loss found the most volume loss in the mid-cheek, plus laxity (looseness) in the central neck (Jafar et al., 2024).

A 2025 review of 23 plastic-surgery articles said GLP-1 drugs cause changes "resembling advanced aging," but noted that its conclusions were "limited by study biases" (Daneshgaran et al., 2025). A 2026 review of tirzepatide in dermatology said facial volume loss claims "warrant cautious interpretation" (El-Amawy et al., 2026).

In UK Mounjaro communities, people often describe it as weight-loss face rather than a drug effect. The limited evidence leans that way, but nobody has tested tirzepatide's effect on facial tissue directly. For changes below the jaw, see our guide to neck skin after GLP-1 weight loss. Evidence: Limited.

Is Mounjaro face the same as Zepbound face and Ozempic face?

Mounjaro face and Zepbound face are the same thing, because both brands contain tirzepatide. Ozempic face is the name for the same weight-loss pattern on semaglutide, which is a different drug.

Is Mounjaro face worse than Ozempic face?

No study has compared faces on the two drugs. Tirzepatide produced more average weight loss in the one head-to-head trial, and facial volume appears to track weight lost, not brand.

SURMOUNT-5 was a 72-week, open-label phase 3b randomized controlled trial (RCT) of 751 adults with obesity and without diabetes, comparing the maximum tolerated doses of each drug (Aronne et al., 2025). Open-label means participants knew which drug they were on. Eli Lilly funded the trial, which measured no facial outcomes.

In the same trial, waist size fell 18.4 cm on tirzepatide vs 13.0 cm on semaglutide. A 2026 review of energy-based devices notes that facial changes "are not specific to one medication" (Cho et al., 2026).

The label rows come from the Zepbound label and the Wegovy label. Evidence: Limited (one sponsor-funded, open-label RCT; no facial outcomes).

How much does your face change on tirzepatide?

Nobody has measured facial change on tirzepatide specifically. The only objective facial data come from 20 mixed GLP-1 users, who lost a median 9.0% of midface volume after a mean 11.0 kg weight loss.

That study was a retrospective cohort, meaning researchers reviewed existing CT or MRI scans taken before and after a GLP-1 prescription (Sharma et al., 2025). Median age was 54, and scans were taken a mean 321 days apart. The work came from Vanderbilt, funding wasn't reported, and results weren't broken out by drug.

Only the superficial fat loss, not the deep fat loss, correlated with weight lost. A 2026 review similarly says midfacial loss "seems to occur mainly in superficial fat compartments" (Frank et al., 2026).

The ~15% figure is our own arithmetic. SURMOUNT-1 was a 72-week, double-blind phase 3 RCT of 2,539 adults without diabetes, funded by Eli Lilly. Participants started at a mean 104.8 kg, and those on 15 mg lost a mean 20.9%, which works out to about 21.9 kg if applied to that average (Jastreboff et al., 2022). Applying the 7% ratio to that loss is an untested extrapolation. The imaging cohort lost only 11.0 kg on average, and nobody has checked whether the ratio holds at larger losses. Evidence: Early / preliminary.

Are you losing fat or muscle on Mounjaro?

Mostly fat. In a SURMOUNT-1 body-scan substudy, about 75% of the weight lost on tirzepatide was fat and 25% was lean mass, the same split seen on placebo (Look et al., 2025).

The substudy used DXA, a low-dose X-ray scan that separates fat from lean mass, at baseline and week 72 in 160 people (124 on tirzepatide, 36 on placebo). Weight fell 21.3% on tirzepatide vs 5.3% on placebo, and several authors are Eli Lilly employees. Lean mass includes muscle plus water and organs, and this was a whole-body measure, so it can't tell you what happened in your face.

A 2026 meta-analysis of 20 RCTs and 15,782 people, measured by DXA or MRI, compared the lean share of weight lost across treatments (Eisa and Barood, 2026). Lifestyle programs alone were comparable to incretins (p=0.42). Results varied across trials (I² 68%), and the authors concluded the proportion is broadly comparable.

A 2025 network meta-analysis of 22 RCTs and 2,258 people framed the findings differently (Karakasis et al., 2025). It also found lean mass was about 25% of weight lost, with relative lean mass (as a share of baseline) unaffected. It said tirzepatide 15 mg and semaglutide 2.4 mg, the most effective drugs for weight loss, were "among the least effective in preserving lean mass" in absolute terms.

The 2 findings can both hold, because a larger total loss means more kilograms of lean mass even at a similar share. A 2024 review estimated incretin lean loss at about 10%, or about 6 kg (Locatelli et al., 2024). It noted that supervised resistance training for more than 10 weeks can add about 3 kg of lean mass and about 25% strength in general populations, though this hasn't been tested in incretin users. Evidence: Limited (tirzepatide substudy); Mixed / contested (meta-analyses agree on a ~25% lean share but frame tirzepatide differently).

Who is more likely to get Mounjaro face?

According to Cleveland Clinic, people who lose weight faster and older adults are more likely to notice it, because older adults have lower reserves of fat under the skin (Cleveland Clinic, 2025). No study has measured these risk factors on tirzepatide or put numbers on them.

The same page says rapid weight loss lowers elastin and collagen. That's the clinic's claim, not a finding tested in GLP-1 users. The imaging cohort had a median age of 54, but it was too small to compare age groups (Sharma et al., 2025).

People starting Mounjaro often ask whether losing more than about 1.5 kg a week makes sagging inevitable. No trial has compared facial outcomes by rate of loss or by dose. Cleveland Clinic suggests telling your provider about facial concerns when you start treatment. Evidence: Limited (clinician opinion; no quantified risk data).

Can you prevent Mounjaro face?

No step has been shown to prevent Mounjaro face, because no study has tested prevention on tirzepatide. Cleveland Clinic suggests several measures, and the evidence behind each one varies (Cleveland Clinic, 2025).

• Pace of loss. Cleveland Clinic's endocrinologist suggests slower loss of "about one to two pounds per week." Your pace depends on your dose and your health, so this is a conversation to have with your prescriber. No study links pace to facial outcomes. Evidence: Limited (clinician opinion).
• Protein and resistance training. In the 20-RCT meta-analysis, lifestyle plus resistance training had the lowest lean share of weight lost (17.5%). The authors say resistance training, protein and monitoring can preserve muscle (Eisa and Barood, 2026). None of these studies measured faces. Evidence: Limited for the face (whole-body data only).
• Nutrition. A 2026 narrative review estimated that about 22.4% of GLP-1 users have at least 1 documented deficiency within a year, with vitamin D deficiency at 13.6% at 12 months (Karlin et al., 2026). The authors say deficiencies "may plausibly compound" skin changes but rate their evidence as level 5 (expert opinion). No study sets a protein target for facial skin on tirzepatide, so a clinician or registered dietitian is the person to ask. Evidence: Limited.
• Hydration, sunscreen and skincare. The AAD suggests a gentle cleanser, a moisturizer with ceramides and antioxidants applied to damp skin, and broad-spectrum, water-resistant SPF 30+ (AAD, 2026). It also suggests considering retinoids, which may irritate dry skin. These steps target skin quality, not lost fat. See our barrier basics and skincare routine order. Evidence: Limited (expert guidance; not tested on GLP-1 faces).

Does Mounjaro face go away?

Usually not on its own while weight stays off. Cleveland Clinic says "Ozempic face won't fade with time." If weight is maintained, the effects likely stay, and if weight is regained, the face may look fuller (Cleveland Clinic, 2025).

SURMOUNT-4, a Lilly-sponsored randomized withdrawal trial, shows what happened to weight, though not to faces, when tirzepatide was swapped for placebo (Aronne et al., 2024).

A recurring question comes from people in their late 20s who lost about 50 lb in a few months. They want to know whether hollow cheeks, under-eye hollowing and a softer jawline will tighten on their own. Some long-term users also report a gaunt look midway that softened at goal weight once they ate at maintenance. These are anecdotes, and no data support or contradict them. Our guide to whether loose skin after weight loss goes away covers the body-wide evidence. Evidence: Limited.

What can you do about Mounjaro face?

Cleveland Clinic calls it harmless and says it doesn't need treatment unless you want it (Cleveland Clinic, 2025). If you do want treatment, the evidence is thin. Our guides to fixing Ozempic face and dermal fillers for Ozempic face cover the options in depth.

The randomized trial was a 25-person, double-blind split-face study of a SkinCeuticals topical regimen. Laxity fell 16% on the treated side at 4 weeks (P<.001), with no significant change on the placebo side (Moradi A et al., 2026). By week 12, after 1 focused-ultrasound session on both sides, laxity was down 44% and marionette lines 34%. Two authors are SkinCeuticals employees, and participants lost only 3.7 lb on average, so the trial says little about skin during active weight loss.

An open-label study of a volumizing cream (33 enrolled, 29 completed, 12 weeks) reported wrinkle severity down 20.7% and skin plus subcutaneous thickness up 20.1% (Nguyen et al., 2026). It also reported transepidermal water loss (water escaping through the skin barrier) down 12.7%, hydration up 21.8% and firmness up 22.5%. With no control group, the cream can't be separated from time or simple moisturizing. Its senior author consults for companies including Lilly and Galderma.

For injectables, a 41-person open-label study tested Sculptra (PLLA, poly-L-lactic acid, a collagen-stimulating injectable) plus hyaluronic acid (HA) filler. It reported better skin quality and contour over 9 months with no treatment-related adverse events. Galderma, which makes both products, funded, designed and analyzed the study (Lorenc et al., 2026).

A 4-clinician consensus said these treatments "have not yet been widely studied in this population" and that timing within the weight-loss journey matters. Allergan Aesthetics funded the writing support (Moradi et al., 2026). A German review concluded that "systematic studies on the effectiveness and safety of this treatment are lacking" (Seidel and Bode, 2025). A device review found that no device has restored fat, dermis and muscle in prospective GLP-1-specific studies (Cho et al., 2026).

Demand is rising anyway. In a survey of 406 health care professionals, respondents reported a mean 137% increase in GLP-1 patients from 2023 to 2024 and considered HA filler best for an average 47% of patients (Fabi et al., 2026). Two of the authors work for Allergan Aesthetics.

A non-peer-reviewed preprint looked at women with diabetes and hypertension, with 23,349 matched per group. It found 5-year upper eyelid surgery rates of 0.41% with GLP-1 drugs vs 0.15% in controls (HR 2.22), and no significant link for non-GLP-1 weight loss (Almeida et al., 2026). That's an association only, with no drug-specific breakdown.

No study in our sources covers polynucleotides or compares treating during weight loss with waiting until weight is stable. Topical peptides can't replace lost fat volume. See peptides for loose skin and peptide ingredients ranked by evidence. Evidence: Limited.

Does tirzepatide affect skin directly?

No direct effect on facial tissue has been shown in humans. Label skin side effects such as hair loss and injection-site reactions, by contrast, are well measured.

A 2025 mechanistic review proposes that GLP-1 receptors on fat-derived stem cells and fibroblasts (collagen-making cells) could play a role. It argues that facial aging "is not exclusively related to decreased facial fat" (Paschou et al., 2025). The AAD states that "GLP-1 drugs affect your collagen and muscles, along with your fat cells" (AAD, 2026), but that's an expert view. A 2026 review notes that "Direct GLP-1RA effects on dermal cells remain preclinical" (Karlin et al., 2026).

In 10 abdominal fat samples, GLP-1 users had 11.0 vs 44.8 fat-derived stem cells per mm² compared with controls (p=.039). The authors call this a "potential mechanism" (Firsowicz et al., 2026). The study is tiny and looked at abdominal fat, not facial fat.

The Zepbound label says most hypersensitivity reactions were skin reactions such as rash or itching. It says hair loss was "associated with weight reduction" and affected 7.1% of women vs 0.5% of men, and no one stopped Zepbound because of it. The Mounjaro label reports hypersensitivity in 3.2% vs 1.7% on placebo, "sometimes severe (e.g., urticaria and eczema)," and lists hair loss only in post-marketing reports.

A 2026 meta-analysis of 9 studies (7 RCTs) covering 4,114 GLP-1 users found hair loss risk 3.25 times higher than with placebo, with a pooled rate of 3.9%. The authors reported no competing interests (Cheng et al., 2026).

Two case reports describe facial nodules in old filler after starting compounded tirzepatide (Luke, 2026; Moore, 2026). A response letter notes that infection or biofilm wasn't excluded (Pitak-Arnnop et al., 2026). In a single case, facial swelling in HA filler after starting Ozempic resolved with hyaluronidase (de Oliveira Ciaramicolo et al., 2024). Hives, rash, swelling or lumps are worth raising with your prescriber.

For more, see Zepbound skin side effects, Mounjaro skin sensitivity, GLP-1 hair loss and our FDA adverse event report analysis. Evidence: Well-established (label trial data and meta-analysis for hair loss); Early / preliminary (any direct effect on facial tissue).

Mounjaro face before and after: what photos can and can't tell you

A Mounjaro face before and after photo shows one person's result, not what tirzepatide does to faces in general. No trial has published standardized facial photos on tirzepatide, so this page uses no patient photos. For the semaglutide side, see what Wegovy face before and after photos actually show.

Photo-rating studies after surgical weight loss show how mixed the results are. In one study, 40 blinded raters judged 7 facelift patients who'd lost more than 100 lb as looking 5.1 years older than 11 controls (Couto et al., 2015). In another, about 100 raters judged 14 bariatric patients as older but more attractive, and only 5 of the 14 had a significant change in perceived age (Papoian et al., 2015).

Scale also matters when you compare photos. In SURMOUNT-1, half of people on 10 mg and 57% on 15 mg lost at least 20% of their weight, compared with 3% on placebo (Jastreboff et al., 2022). For what semaglutide before-and-after images do and don't show, see Wegovy face before and after. Evidence: Limited.

Where the evidence stops

• No tirzepatide facial data. No trial has photographed, scanned or rated faces on Mounjaro or Zepbound.
• No facial head-to-head. SURMOUNT-5 compared weight, not faces.
• One small imaging study. The 7% per 10 kg figure comes from 20 mixed GLP-1 users with an 11.0 kg mean loss.
• No timeline study. Scans in that study were a mean 321 days apart, so nobody knows how fast changes appear.
• No quantified risk factors. Faster loss and older age come from clinician opinion, and no data tie rate of loss, dose, protein or regain to the face.
• Thin treatment evidence. There's one small, industry-linked randomized topical trial, no randomized trial of fillers or devices, and no study of peptide serums or polynucleotides in GLP-1 users.
• Direct skin effects are preclinical.

FAQ

References

1. Eli Lilly. MOUNJARO (tirzepatide) prescribing information, revised 08/2026. DailyMed. 2026. US label; type 2 diabetes indication. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
2. Eli Lilly. ZEPBOUND (tirzepatide) prescribing information, revised 08/2026. DailyMed. 2026. US label; weight management and OSA; pooled SURMOUNT-1 and -2 adverse reactions. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. Novo Nordisk. WEGOVY (semaglutide) prescribing information, revised 06/2026. DailyMed. 2026. US label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
4. Cleveland Clinic (Makin V, quoted endocrinologist). "Ozempic Face": What It Is and How To Avoid It. Cleveland Clinic Health Essentials. 2025. Consumer health article (March 5, 2025). https://health.clevelandclinic.org/ozempic-face
5. American Academy of Dermatology. How can GLP-1 drugs affect my skin, hair, and nails? AAD.org. 2026. Patient education page; last updated 2/17/26. https://www.aad.org/public/everyday-care/skin-care-secrets/prevent-skin-problems/glp1-drugs-and-side-effects
6. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. Phase 3 double-blind RCT, n=2,539, 72 weeks; funded by Eli Lilly. https://pubmed.ncbi.nlm.nih.gov/35658024/
7. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. Phase 3b open-label RCT, n=751, 72 weeks; funded by Eli Lilly. https://pubmed.ncbi.nlm.nih.gov/40353578/
8. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. n=160, 72 weeks; several authors Eli Lilly employees. https://pubmed.ncbi.nlm.nih.gov/39996356/
9. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. 783 in lead-in, 670 randomized, 88 weeks total; Lilly-sponsored. https://pubmed.ncbi.nlm.nih.gov/38078870/
10. Sharma RK, et al. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngol Head Neck Surg. 2025. Retrospective cohort, n=20; funding not reported. https://pubmed.ncbi.nlm.nih.gov/40407186/
11. Jafar AB, et al. Soft Tissue Facial Changes Following Massive Weight Loss Secondary to Medical and Surgical Bariatric Interventions: A Systematic Review. Aesthet Surg J Open Forum. 2024. 13 studies + 1 abstract; observational. https://pubmed.ncbi.nlm.nih.gov/39346804/
12. Daneshgaran G, et al. "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthet Surg J Open Forum. 2025. 23 articles; no funding or conflicts declared. https://pubmed.ncbi.nlm.nih.gov/40626110/
13. El-Amawy HS. Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review. An Bras Dermatol. 2026. Narrative review. https://pubmed.ncbi.nlm.nih.gov/41483501/
14. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026. 20 RCTs, n=15,782; I² 68%. https://pubmed.ncbi.nlm.nih.gov/41877354/
15. Karakasis P, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025. 22 RCTs, n=2,258. https://pubmed.ncbi.nlm.nih.gov/39719170/
16. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes Care. 2024. Narrative review. https://pubmed.ncbi.nlm.nih.gov/38687506/
17. Frank K, et al. GLP-1-Induced Weight Loss and the Face: Anatomical Mechanisms and Rationale for Collagen-Stimulating and Volumizing Aesthetic Treatments. Dermatol Surg. 2026. Narrative review; expert opinion. https://pubmed.ncbi.nlm.nih.gov/42210888/
18. Paschou IA, et al. GLP-1RA and the possible skin aging. Endocrine. 2025. Mechanistic review (hypothesis); no competing interests. https://pubmed.ncbi.nlm.nih.gov/40498168/
19. Firsowicz M, et al. Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study. Dermatol Surg. 2026. 10 samples; funding not stated in abstract. https://pubmed.ncbi.nlm.nih.gov/42210886/
20. Karlin J, et al. The Impact of Glucagon-Like Peptide-1 Receptor Agonist-Induced Nutritional Deficiencies on Skin Health: A Narrative Review With a Proposed Framework for the Aesthetic Practitioner. Aesthet Surg J Open Forum. 2026. Level 5 evidence. https://pubmed.ncbi.nlm.nih.gov/42872147/
21. Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2026. 9 studies (7 RCTs), n=4,114; no competing interests. https://pubmed.ncbi.nlm.nih.gov/42155605/
22. Nguyen N, et al. Topical Volumizing Cream Improves Facial Volume and Skin Health in Adults With Rapid Weight Loss From Pharmacologic (GLP-1/GIP Agonists), Surgical, or Behavioral Interventions. J Cosmet Dermatol. 2026. Open-label single-arm, n=33 (29 completed), 12 weeks; funding not stated; senior author consults for industry. https://pubmed.ncbi.nlm.nih.gov/41556403/
23. Moradi A, et al. Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy. Dermatol Ther (Heidelb). 2026. Double-blind randomized split-face, n=25, 12 weeks; two SkinCeuticals employees. https://pubmed.ncbi.nlm.nih.gov/41781778/
24. Lorenc ZP, et al. A Multicenter, Open-Label Study of Combined Poly-L-Lactic Acid and Hyaluronic Midface Filler Regimen Enhances Facial Harmony and Skin Quality in GLP-1 Medication Users. Aesthet Surg J. 2026. Open-label, uncontrolled, n=41, 9 months; funded, designed and analyzed by Galderma. https://pubmed.ncbi.nlm.nih.gov/41243519/
25. Moradi A, et al. Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations. Aesthet Surg J Open Forum. 2026. 4 clinicians; Allergan Aesthetics funded writing support. https://pubmed.ncbi.nlm.nih.gov/41768029/
26. Fabi S, et al. Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. Dermatol Surg. 2026. Opinion survey, n=406; two Allergan Aesthetics employees. https://pubmed.ncbi.nlm.nih.gov/42210883/
27. Seidel DU, Bode S. Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine. HNO. 2025. Review. https://pubmed.ncbi.nlm.nih.gov/40767957/
28. Cho CH, et al. Energy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework. Clin Cosmet Investig Dermatol. 2026. Review; concepts hypothesis-generating. https://pubmed.ncbi.nlm.nih.gov/42893183/
29. Catalfamo L, et al. "Ozempic Face": An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience. J Clin Med. 2025. Uncontrolled case series, n=24, ≥12 months follow-up; device provided by InMode Italy. https://pubmed.ncbi.nlm.nih.gov/40806889/
30. Almeida VFA, et al. Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty. Res Sq. 2026. Retrospective matched cohort, 23,349 per arm; no conflicts. https://pubmed.ncbi.nlm.nih.gov/42245794/
31. Couto RA, et al. Objective Assessment of Facial Rejuvenation After Massive Weight Loss. Aesthetic Plast Surg. 2015. 7 patients vs 11 controls; 40 blinded raters. https://pubmed.ncbi.nlm.nih.gov/26311559/
32. Papoian V, et al. Effects of Bariatric Surgery on Facial Features. Arch Plast Surg. 2015. 14 patients; about 100 raters. https://pubmed.ncbi.nlm.nih.gov/26430627/
33. Luke M, et al. Facial nodules following filler injections after initiating compounded tirzepatide use; Moore LC, et al. Inflammation-mediated facial nodules to compounded tirzepatide; Pitak-Arnnop P, et al. Insufficient exclusion of infectious and biofilm-related complications in reported tirzepatide-associated filler nodules. JAAD Case Rep. 2026. Two case reports and a reply letter. https://pubmed.ncbi.nlm.nih.gov/42088720/ ; https://pubmed.ncbi.nlm.nih.gov/42598502/ ; https://pubmed.ncbi.nlm.nih.gov/42598504/
34. de Oliveira Ciaramicolo N, et al. Late Facial Edema After Lip Filling With Hyaluronic Acid: Possible Association With the Use of Ozempic. J Craniofac Surg. 2024. Single case report. https://pubmed.ncbi.nlm.nih.gov/39190785/

Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Talk to your prescriber before making any change to a GLP-1 medication, and to a licensed clinician about any skin or aesthetic treatment.

For educational purposes only; not medical advice. See our disclaimer and research method.